David Neubauer
Research Subjects
Research Interests
David Neubauer has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
- Damjan Osredkar
Department of Child, Adolescent and Developmental Neurology, Division of Pediatrics, University Medical Centre Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia
7 shared publications Darja Paro-Panjan
Department of Neonatology, University Children's Hospital Ljubljana, Ljubljana, Slovenia
5 shared publicationsMetka Derganc
University Medical Centre Ljubljana, Department of Paediatric Surgery and Intensive Care, Ljubljana, Slovenia
4 shared publications- Zvonka Rener-Primec
Department of Child, Adolescent, and Developmental Neurology, Children's Hospital, University Medical Centre Ljubljana, Slovenia; Department of Paediatrics, Faculty of Medicine, University of Ljubljana, Slovenia
3 shared publications Štefan Kopač
3 shared publicationsAnja Troha Gergeli
UMCL, Children's Hospital, Ljubljana, Slovenia
2 shared publications
Latest Publications
- Open Access
Risks of Unregulated Home-Made Cannabis Products Used by Parents to Treat Refractory Epilepsy in Their Children
Introduction: Some parents initiate treatment with non-prescription, home-made (unlabeled and unregulated) cannabis products for their children with refractory epilepsy without consulting their physicians. This study aimed to analyze the composition of these products in a pediatric cohort. Methods: Home-made cannabis samples were analyzed for cannabinoid content, cannabidiol (CBD):Δ9-tetrahydrocannabinol (THC) ratio, and potential contaminants. Results: Sixty home-made cannabis samples from 31 patients were analyzed. The most frequently detected cannabinoids were CBD, THC, and their acidic forms. The CBD:THC ratio varied significantly, with the most common ratio ranging from 1:1 to 10:1 (25.0%). Approximately 11.7% of the samples contained mainly CBD, 38.3% contained more THC than CBD, and 18.3% contained primarily THC with undetectable CBD levels. Conclusions: Health professionals should strongly discourage the use of unregulated home-made cannabis products, as undisclosed and highly variable cannabinoid content with often elevated THC levels and potential contaminants present serious health risks for children with refractory epilepsy.
Open AccessRisks of Unregulated Home-Made Cannabis Products Used by Parents to Treat Refractory Epilepsy in Their Children
Introduction: Some parents initiate treatment with non-prescription, home-made (unlabeled and unregulated) cannabis products for their children with refractory epilepsy without consulting their physicians. This study aimed to analyze the composition of these products in a pediatric cohort. Methods: Home-made cannabis samples were analyzed for cannabinoid content, cannabidiol (CBD):Δ9-tetrahydrocannabinol (THC) ratio, and potential contaminants. Results: Sixty home-made cannabis samples from 31 patients were analyzed. The most frequently detected cannabinoids were CBD, THC, and their acidic forms. The CBD:THC ratio varied significantly, with the most common ratio ranging from 1:1 to 10:1 (25.0%). Approximately 11.7% of the samples contained mainly CBD, 38.3% contained more THC than CBD, and 18.3% contained primarily THC with undetectable CBD levels. Conclusions: Health professionals should strongly discourage the use of unregulated home-made cannabis products, as undisclosed and highly variable cannabinoid content with often elevated THC levels and potential contaminants present serious health risks for children with refractory epilepsy.
- 13 September 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (18) , 2367-2373
Pharmacogenomics and pediatric drug development: science and political power. A narrative review
IntroductionPharmacogenomics (PGx) investigates how genomes control enzyme expression. Developmental pharmacology (DP) describes the temporal sequence of enzymes impacting absorption, distribution, metabolism, and excretion (ADME) of food and drugs.Areas coveredUS and European Union (EU) legislation facilitate and/or enforce pediatric studies for all new drugs, called overall 'pediatric drug development' (PDD). DP and PDD look at patients' chronological age, but oscillate between legal and physiological meanings of the term 'child.' Children's bodies become mature with puberty.Expert opinionDecades after first DP observations in babies, PGx offers a better understanding of the variability of safety and efficacy of drugs, of the process of aging, and of shifting enzyme patterns across aging. We should rethink and revise outdated interpretations of ADME changes in minors. The Declaration of Helsinki forbids pointless studies that some pediatric researchers and regulatory agencies, more so the EMA than the FDA, demand pointless pediatric studies is regrettable. Medicine needs to differentiate between legal and physiological meanings of the term 'child' and should use objective measures of maturity.
- 13 September 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (18) , 2367-2373
Pharmacogenomics and pediatric drug development: science and political power. A narrative review
IntroductionPharmacogenomics (PGx) investigates how genomes control enzyme expression. Developmental pharmacology (DP) describes the temporal sequence of enzymes impacting absorption, distribution, metabolism, and excretion (ADME) of food and drugs.Areas coveredUS and European Union (EU) legislation facilitate and/or enforce pediatric studies for all new drugs, called overall 'pediatric drug development' (PDD). DP and PDD look at patients' chronological age, but oscillate between legal and physiological meanings of the term 'child.' Children's bodies become mature with puberty.Expert opinionDecades after first DP observations in babies, PGx offers a better understanding of the variability of safety and efficacy of drugs, of the process of aging, and of shifting enzyme patterns across aging. We should rethink and revise outdated interpretations of ADME changes in minors. The Declaration of Helsinki forbids pointless studies that some pediatric researchers and regulatory agencies, more so the EMA than the FDA, demand pointless pediatric studies is regrettable. Medicine needs to differentiate between legal and physiological meanings of the term 'child' and should use objective measures of maturity.
- 29 June 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 52, 10-19
Improving paediatric movement disorders care: Insights on rating scales utilization and clinical practice
- 29 June 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 52, 10-19
Improving paediatric movement disorders care: Insights on rating scales utilization and clinical practice
- 15 June 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 52, 20-28
Perspectives of cerebral palsy experts on access to health care in Europe
- 15 June 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 52, 20-28
Perspectives of cerebral palsy experts on access to health care in Europe
- Open Access
- 19 June 2023
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 36, 100986
Clinical and genetic characteristics of a patient with phosphoribosyl pyrophosphate synthetase 1 deficiency and a systematic literature review
- 19 June 2023
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 36, 100986
Open AccessClinical and genetic characteristics of a patient with phosphoribosyl pyrophosphate synthetase 1 deficiency and a systematic literature review
- Open Access
- 3 May 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (3) , e677
Biallelic ATOH1 Gene Variant in Siblings With Pontocerebellar Hypoplasia, Developmental Delay, and Hearing Loss
Background and Objectives To report on the novel association of biallelic variant in atonal basic helix-loop-helix transcription factor 1 (ATOH1) gene and pontocerebellar hypoplasia (PCH), severe global developmental delay, intellectual disability, and hearing loss in a family with 2 affected siblings. Methods A detailed clinical assessment and exome sequencing of peripheral blood sample were performed. Segregation analysis with Sanger sequencing and structural modeling of the variant was performed to support the pathogenicity of the variant. Results A homozygous missense variant (NM_005172.1:c.481C>G) in the ATOH1 gene was identified in the proband and his affected sister. The segregation analysis subsequently confirmed its segregation with an apparently recessive PCH in this family. ATOH1 encodes for the atonal basic helix-loop-helix (bHLH) transcription factor 1, a core transcription factor in the developing cerebellum, brainstem, and dorsal spinal cord, and in the ear. The identified variant results in the p.(Arg161Gly) amino acid substitution in the evolutionarily conserved DNA-binding bHLH domain of the ATOH1 protein. Biallelic missense variants in this domain were previously reported to result in disordered cerebellar development and hearing loss in animal models. In silico homology modeling revealed that p.Arg161Gly in ATOH1 protein probably disrupts a salt bridge with DNA backbone phosphate and increases the flexibility of the bHLH helix–both of which together affect the binding capability of the bHLH domain to the DNA. Discussion Based on the sequencing results and evidence from structural modeling of the identified variant, as well as with previous reports of ATOH1 gene disruption, we conclude that ATOH1 may represent a novel candidate gene associated with the phenotype of PCH, global developmental delay, and hearing loss in humans.
- 3 May 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (3) , e677
Open AccessBiallelic ATOH1 Gene Variant in Siblings With Pontocerebellar Hypoplasia, Developmental Delay, and Hearing Loss
Background and Objectives To report on the novel association of biallelic variant in atonal basic helix-loop-helix transcription factor 1 (ATOH1) gene and pontocerebellar hypoplasia (PCH), severe global developmental delay, intellectual disability, and hearing loss in a family with 2 affected siblings. Methods A detailed clinical assessment and exome sequencing of peripheral blood sample were performed. Segregation analysis with Sanger sequencing and structural modeling of the variant was performed to support the pathogenicity of the variant. Results A homozygous missense variant (NM_005172.1:c.481C>G) in the ATOH1 gene was identified in the proband and his affected sister. The segregation analysis subsequently confirmed its segregation with an apparently recessive PCH in this family. ATOH1 encodes for the atonal basic helix-loop-helix (bHLH) transcription factor 1, a core transcription factor in the developing cerebellum, brainstem, and dorsal spinal cord, and in the ear. The identified variant results in the p.(Arg161Gly) amino acid substitution in the evolutionarily conserved DNA-binding bHLH domain of the ATOH1 protein. Biallelic missense variants in this domain were previously reported to result in disordered cerebellar development and hearing loss in animal models. In silico homology modeling revealed that p.Arg161Gly in ATOH1 protein probably disrupts a salt bridge with DNA backbone phosphate and increases the flexibility of the bHLH helix–both of which together affect the binding capability of the bHLH domain to the DNA. Discussion Based on the sequencing results and evidence from structural modeling of the identified variant, as well as with previous reports of ATOH1 gene disruption, we conclude that ATOH1 may represent a novel candidate gene associated with the phenotype of PCH, global developmental delay, and hearing loss in humans.
- 1 February 2022
- Published by Elsevier in Early Human Development
- Vol. 165, 105533
The impact of birthweight on the development of cerebral palsy: A population-based matched case-control study
- 1 February 2022
- Published by Elsevier in Early Human Development
- Vol. 165, 105533
The impact of birthweight on the development of cerebral palsy: A population-based matched case-control study
- 1 September 2020
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 28, 205-213
Reduced white-matter integrity and lower speed of information processing in adolescents with mild and moderate neonatal hypoxic-ischaemic encephalopathy
- 1 September 2020
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 28, 205-213
Reduced white-matter integrity and lower speed of information processing in adolescents with mild and moderate neonatal hypoxic-ischaemic encephalopathy
- Open Access
- 1 January 2019
- Published by Elsevier in Current Therapeutic Research
- Vol. 90, 86-91
Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia
- 1 January 2019
- Published by Elsevier in Current Therapeutic Research
- Vol. 90, 86-91
Open AccessQuestionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia